Today (January 7), Boehringer Ingelheim China and Shanghai Pharma Holdings held a ceremony to mark the launch of their Global Strategy cooperation, announcing that both parties have reached a strategic cooperation for the national retail market of Etacryn (generic name: Linagliptin). Starting from January 1, 2025, the distribution and promotion of Boehringer Ingelheim's product Etacryn (generic name: Linagliptin) through non-Medical Institutions channels in China will be fully handled by Shanghai Pharma Holdings.
勃林格殷格翰中国和上药控股达成战略合作
Boehringer Ingelheim China and Shanghai Pharma Holdings have reached a Global Strategy cooperation.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney